DMP-728 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413864

CAS#: 153345-74-5

Description: DMP-728 free base is a highly potent and selective GPIIbDIIa antagonist

Chemical Structure

img
DMP-728 free base
CAS# 153345-74-5
Instruction

Theoretical Analysis

MedKoo Cat#: 413864
Name: DMP-728 free base
CAS#: 153345-74-5
Chemical Formula: C25H36N8O7
Exact Mass: 560.27
Molecular Weight: 560.610
Elemental Analysis: C, 53.56; H, 6.47; N, 19.99; O, 19.98

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: DMP-728 free base; XL118; XL 118; XL-118

IUPAC/Chemical Name: 2-((5S,11S,14R)-14-ethyl-11-(3-guanidinopropyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-1(1,3)-benzenacyclohexadecaphane-5-yl)acetic acid

InChi Key: JWRYVLUXFOYZCH-SQNIBIBYSA-N

InChi Code: InChI=1S/C25H36N8O7/c1-3-16-24(40)33(2)18(8-5-9-28-25(26)27)23(39)30-13-19(34)31-17(11-20(35)36)22(38)29-12-14-6-4-7-15(10-14)21(37)32-16/h4,6-7,10,16-18H,3,5,8-9,11-13H2,1-2H3,(H,29,38)(H,30,39)(H,31,34)(H,32,37)(H,35,36)(H4,26,27,28)/t16-,17+,18+/m1/s1

SMILES Code: CC[C@H]1NC(c2cc(CNC([C@@H](NC(CNC([C@@H](N(C1=O)C)CCCNC(N)=N)=O)=O)CC(O)=O)=O)ccc2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 560.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mousa SA, DeGrado WF, Mu DX, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation. 1996 Feb 1;93(3):537-43. doi: 10.1161/01.cir.93.3.537. PMID: 8565173.

2: Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994 Jan;89(1):3-12. doi: 10.1161/01.cir.89.1.3. PMID: 8281661.

3: Reilly TM, Mousa SA, Racanelli AL, Thoolen MJ, Flint SK, Bozarth JM, Mu DX, Walton HL. A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2195-9. doi: 10.1161/01.atv.15.12.2195. PMID: 7489242.

4: Mousa SA, Flint S, Lorelli W, Hassell S, Bozarth J, De Grado W, Reilly TM. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. Thromb Res. 1994 Oct 15;76(2):109-19. doi: 10.1016/0049-3848(94)90182-1. PMID: 7863463.

5: Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol. 1994 Apr;23(4):681-9. doi: 10.1097/00005344-199404000-00025. PMID: 7516023.

6: Huang J, Rebello SS, Faul JD, Lucchesi BR. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Pharmacology. 1999 May;58(5):252-64. doi: 10.1159/000028288. PMID: 10087466.

7: Saitoh H, Aungst BJ. Prodrug and analog approaches to improving the intestinal absorption of a cyclic peptide, GPIIb/IIIa receptor antagonist. Pharm Res. 1997 Aug;14(8):1026-9. doi: 10.1023/a:1012149227756. PMID: 9279884.

8: Michaelis W, Turlapaty P, Gray J, Fiske WD, Faulkner E, Kornhauser D, Mousa SA. Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects. Clin Pharmacol Ther. 1998 Mar;63(3):384-92. doi: 10.1016/S0009-9236(98)90170-9. PMID: 9542482.

9: Wu ST, Stampfli HF, Banks CM, Emm TA, Kapil RP, Padovani PK, Lee WM Jr, Huang SM. Determination of DMP 728, a IIb/IIIa receptor antagonist, in rat and dog plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):254-60. doi: 10.1016/0378-4347(94)80097-9. PMID: 7952079.

10: Aungst BJ, Saitoh H. Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist. Pharm Res. 1996 Jan;13(1):114-9. doi: 10.1023/a:1016093704095. PMID: 8668658.